Open AccessComparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer
Author(s) -
Ian Chau,
Dieter Ayers,
Sarah Goring,
Shan Cope,
Beata Korytowsky,
Pranav Abraham
Publication year - 2020
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2019-0145
Subject(s) - nivolumab , medicine , hazard ratio , refractory (planetary science) , randomized controlled trial , cancer , clinical trial , population , relative risk , oncology , surgery , confidence interval , immunotherapy , environmental health , physics , astrobiology
Aim: To determine the effectiveness of nivolumab compared with routine clinical practice (RCP) for patients with gastric or gastroesophageal cancer refractory to, or intolerant of, two or more previous regimens, using real-world electronic patient records from a US population, a single-arm trial (CheckMate 032) and a randomized controlled trial in an Asian setting (ATTRACTION-2). Materials & methods: A simulated treatment comparison was conducted to predict overall survival for patients treated with nivolumab compared with RCP in the USA. Results: Results of the indirect simulated treatment comparison suggest that nivolumab is associated with a 50% reduction in the risk of all-cause mortality relative to RCP (Hazard ratio: 0.50; 95% CI: 0.36, 0.68). Conclusion: The survival benefit of nivolumab may extend more generally to the USA.